Hepion Pharmaceuticals (HEPA) announced that Kaouthar Lbiati has been named as interim CEO, effective June 16, 2025. Dr. Lbiati is replacing John Brancaccio, who is retiring for personal reasons. Lbiati has served on Hepion’s Board of Directors since June 2022 and brings over 15 years of global leadership experience in both biotech and large pharmaceutical companies. She also serves on the board of Theralase Technologies
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HEPA: